Hongfeng Quan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongfeng Quan has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Lin Dong
School of Pharmacy, Ningxia Medical University, Yinchuan, P. R. China
2 shared publications Meng Zhan
School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China
2 shared publicationsMiao Ma
School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China
2 shared publicationsXiyan Mo
School of Pharmacy, Ningxia Medical University, Yinchuan 750004, China
2 shared publications- Hao Zhou
School of Pharmacy, Ningxia Medical University, Yinchuan, 750004, China
1 shared publication - Hui Shi
Department of Basic Pharmacology and Toxicology, School of Pharmacy, Ningxia Medical University, Yinchuan, China
1 shared publication
Latest Publications
- 15 August 2025
- Published by Elsevier in Fitoterapia
- Vol. 186, 106820
Stellarine A attenuates anxiety in rats through ERK/CREB/BDNF signaling: A 1HNMR metabolomics study revealing metabolic pathways and biomarkers
- 15 August 2025
- Published by Elsevier in Fitoterapia
- Vol. 186, 106820
Stellarine A attenuates anxiety in rats through ERK/CREB/BDNF signaling: A 1HNMR metabolomics study revealing metabolic pathways and biomarkers
- 1 July 2024
- Published by Springer Nature in Chemistry of Natural Compounds
- Vol. 60 (4) , 798-802
Chemical Constituents and Anti-Anxiety Active Sites from Stellaria dichotoma var. lanceolata
- 1 July 2024
- Published by Springer Nature in Chemistry of Natural Compounds
- Vol. 60 (4) , 798-802
Chemical Constituents and Anti-Anxiety Active Sites from Stellaria dichotoma var. lanceolata
- 1 March 2021
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 267, 113478
A review of the ethnobotanical value, phytochemistry, pharmacology, toxicity and quality control of Tussilago farfara L. (coltsfoot)
- 1 March 2021
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 267, 113478
A review of the ethnobotanical value, phytochemistry, pharmacology, toxicity and quality control of Tussilago farfara L. (coltsfoot)
- Open Access
Effects of Betaine on LPS-Stimulated Activation of Microglial M1/M2 Phenotypes by Suppressing TLR4/NF-κB Pathways in N9 Cells
Microglia mediate multiple facets of neuroinflammation. They can be phenotypically divided into a classical phenotype (pro-inflammatory, M1) or an alternative phenotype (anti-inflammatory, M2) with different physiological characteristics and biological functions in the inflammatory process. Betaine has been shown to exert anti-inflammatory effects. In this study, we aimed to verify the anti-inflammatory effects of betaine and elucidate its possible molecular mechanisms of action in vitro. Lipopolysaccharide (LPS)-activated microglial cells were used as an inflammatory model to study the anti-inflammatory efficacy of betaine and explore its mechanism of regulating microglial polarisation by investigating the morphological changes and associated inflammatory changes. Cytokine and inflammatory mediator expression was also measured by ELISA, flow cytometry, immunofluorescence, and western blot analysis. Toll-like receptor (TLR)-myeloid differentiation factor 88 (Myd88)-nuclear factor-kappa B (NF-κB) p65, p-NF-κB p65, IκB, p-IκB, IκB kinase (IKK), and p-IKK expression was determined by western blot analysis. Betaine significantly mitigated the production of pro-inflammatory cytokines and increased the release of anti-inflammatory cytokines. It promoted the conversion of the microglia from M1 to M2 phenotype by decreasing the expression of inducible nitric oxide synthase and CD16/32 and by increasing that of CD206 and arginase-1. Betaine treatment inhibited the TLR4/NF-κB pathways by attenuating the expression of TLR4-Myd88 and blocking the phosphorylation of IκB and IKK. In conclusion, betaine could significantly alleviate LPS-induced inflammation by regulating the polarisation of microglial phenotype; thus, it might be an effective therapeutic agent for neurological disorders.
Open AccessEffects of Betaine on LPS-Stimulated Activation of Microglial M1/M2 Phenotypes by Suppressing TLR4/NF-κB Pathways in N9 Cells
Microglia mediate multiple facets of neuroinflammation. They can be phenotypically divided into a classical phenotype (pro-inflammatory, M1) or an alternative phenotype (anti-inflammatory, M2) with different physiological characteristics and biological functions in the inflammatory process. Betaine has been shown to exert anti-inflammatory effects. In this study, we aimed to verify the anti-inflammatory effects of betaine and elucidate its possible molecular mechanisms of action in vitro. Lipopolysaccharide (LPS)-activated microglial cells were used as an inflammatory model to study the anti-inflammatory efficacy of betaine and explore its mechanism of regulating microglial polarisation by investigating the morphological changes and associated inflammatory changes. Cytokine and inflammatory mediator expression was also measured by ELISA, flow cytometry, immunofluorescence, and western blot analysis. Toll-like receptor (TLR)-myeloid differentiation factor 88 (Myd88)-nuclear factor-kappa B (NF-κB) p65, p-NF-κB p65, IκB, p-IκB, IκB kinase (IKK), and p-IKK expression was determined by western blot analysis. Betaine significantly mitigated the production of pro-inflammatory cytokines and increased the release of anti-inflammatory cytokines. It promoted the conversion of the microglia from M1 to M2 phenotype by decreasing the expression of inducible nitric oxide synthase and CD16/32 and by increasing that of CD206 and arginase-1. Betaine treatment inhibited the TLR4/NF-κB pathways by attenuating the expression of TLR4-Myd88 and blocking the phosphorylation of IκB and IKK. In conclusion, betaine could significantly alleviate LPS-induced inflammation by regulating the polarisation of microglial phenotype; thus, it might be an effective therapeutic agent for neurological disorders.